Graves N M, Holmes G B, Leppik I E
College of Pharmacy, University of Minnesota, Minneapolis 55455.
Epilepsy Res Suppl. 1988;1:91-9.
Safety and efficacy studies of new antiepileptic drugs require strict adherence to prescribed dosage regimens. Therefore, they provide a unique opportunity to investigate the variability in serum concentrations that are seen in a compliant group of motivated patients. Phenytoin and carbamazepine serum concentrations from two safety and efficacy trials were evaluated for coefficient of variation, difference from baseline concentration, and percent difference. Coefficient of variation for phenytoin was usually less than 20% and was not influenced by baseline serum concentration or frequency of administration. There was no relationship between serum concentration and frequency of administration on carbamazepine coefficient of variation which was less than 25% in most cases. Most PHT differences from baseline were within 5 micrograms/ml, whereas most CBZ differences were within 2 micrograms/ml. Most PHT concentrations were within 30% of each other whereas most CBZ concentrations were within 40% of each other. Data from this study provide information regarding the variability of phenytoin and carbamazepine concentrations under ideal conditions and can be used to set limits for fluctuations of concomitant antiepileptic drugs in safety and efficacy trials or ideal patient care settings.
新型抗癫痫药物的安全性和有效性研究需要严格遵循规定的给药方案。因此,它们为研究一组依从性良好且积极配合的患者血清浓度的变异性提供了独特的机会。对两项安全性和有效性试验中的苯妥英钠和卡马西平血清浓度进行了变异系数、与基线浓度的差异以及百分比差异的评估。苯妥英钠的变异系数通常小于20%,且不受基线血清浓度或给药频率的影响。血清浓度与给药频率之间与卡马西平变异系数无关,在大多数情况下该系数小于25%。大多数苯妥英钠与基线的差异在5微克/毫升以内,而大多数卡马西平的差异在2微克/毫升以内。大多数苯妥英钠浓度彼此相差在30%以内,而大多数卡马西平浓度彼此相差在40%以内。本研究的数据提供了关于理想条件下苯妥英钠和卡马西平浓度变异性的信息,可用于在安全性和有效性试验或理想的患者护理环境中设定联合使用抗癫痫药物波动的限度。